Nervgen Pharma Corp. · NASDAQ:NGEN
Nervgen Pharma — Investor Presentation (April 2022)
29 slides from Nervgen Pharma's investor presentation, Apr 19, 2022
Slide 1: Enabling the Nervous System to Repair Itself
APRIL 19, 2022 Enabling the Nervous System to Repair Itself C O R P O R AT E P R E S E N TAT I O N
Slide 2: Financial Disclosure Statement
Financial Disclosure Statement Not an offer or solicitation: This document is provided for general information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. The contents of this document have not been approved or disappr
Slide 3: NVG-291: A Pipeline in a Product
NVG-291: A Pipeline in a Product STAGE OF DEVELOPMENT TOP-LINE PHASE MARKET INDICATION PRECLINICAL PHASE 1 PHASE 2 1b/2a RESULTS OPPORTUNITY • ~18,000 new patients per year in the US Spinal Cord Injury 2022 2023 • ~300,000 chronic patients • Lifetime costs range from $1 to >$5 million • ~6,000,000 p
Slide 4: Revolutionizing the Treatment of Nervous System Damage
Revolutionizing the Treatment of Nervous System Damage Everyone KNOWS… Everyone BELIEVES… The nervous system is a The nervous system complex system that cannot repair itself controls thought, movement, senses, etc. 4
Slide 5: NVG-291 – First-in-Class Neuroreparative Drug
NVG-291 – First-in-Class Neuroreparative Drug S E V E R E S P I N A L C O R D I N J U RY M O D E L Representative of Placebo Group Representative of NVG-291 Group (Back Legs and Tail Dragging) (Back Legs and Tail Active) Remarkable and robust repair across multiple models 5 Rink et al., 2018
Slide 6: NervGen's Technology Was Invented by Dr. Jerry Silver – the Oracle
NervGen’s Technology Was Invented by Dr. Jerry Silver – the “Oracle” Dr. Silver’s Spinal Cord Research • Discovered why the nervous system does not repair itself STRONG IP PORTFOLIO • Identified the surprising molecules responsible NervGen licensed the technology from Dr. Silver Has Received Numerou
Slide 7: The Evolution of Our Proprietary Science
The Evolution of Our Proprietary Science 1990s 2009 2015 Dr. Silver identified a class of Dr. Silver and collaborators from Harvard Dr. Silver's team then identified molecules called CSPGs, co-discovered that CSPGs bind with a NVG-291, a drug that targets this present in scars in the brain and recep
Slide 8: NVG-291 Allows Neurons to Grow in the Scar
NVG-291 Allows Neurons to Grow in the Scar NVG-291 frees Neuron bound to neuron from CSPGs and unable CSPGs and allows to grow it to grow NVG-291, a 35 amino acid peptide, produced dramatic recovery in a spinal cord injury animal study: the results published in Nature1 are now cited in over 327 publ
Slide 9: The Body's Powerful Innate Repair Mechanisms
The Body’s Powerful Innate Repair Mechanisms Disrupted by CSPGs Repair Mechanisms: Injury Axonal Regeneration Scar Formation The ability of a severed axon to reestablish connectivity with other neurons Injury Brain Upregulation of CSPGs Plasticity The creation of new neuronal connections and rewirin
Slide 10: NVG-291 Takes the Brakes off Natural Repair Mechanisms
NVG-291 Takes the Brakes off Natural Repair Mechanisms Repair Mechanisms: Injury Axonal Regeneration Scar Formation The ability of a severed axon to reestablish connectivity with other neurons Injury Brain Upregulation of CSPGs Plasticity The creation of new neuronal connections and rewiring of exis
Slide 11: NVG-291 Broadly Restores Function
NVG-291 Broadly Restores Function NVG-291 Has Demonstrated Dramatic Repair in multiple animal models of neurological injury/disease, as documented in 15+ peer-reviewed papers ACUTE SPINAL PERIPHERAL MULTIPLE OPTIC CORD INJURY NERVE INJURY SCLEROSIS NEURITIS STROKE • Motor • Motor • Motor • Visual •
Slide 12: NVG-291: Potential to Treat All Types of Nervous System Damage
NVG-291: Potential to Treat All Types of Nervous System Damage TRAUMA DISEASE Acute Spinal Cord Injury Multiple Sclerosis Alzheimer’s Disease Chronic Spinal Cord Injury Stroke NVG-291 ALS Traumatic Brain Injury Frontotemporal Dementia Parkinson’s Disease NervGen Pipeline 12
Slide 13: Experienced Management Team
Experienced Management Team • 30+years of biotech and pharma commercial and development experience Paul Brennan • $3+ billion in M&A, licensing and corporate restructuring transactions President & CEO • >10 products now FDA approved • 25+ years pharma experience and as practicing neurologist conduct
Slide 14: Spinal Cord Injury: No FDA Approved Drug
Spinal Cord Injury No FDA Approved Drug • ~18,000 new patients per year in the US • ~300,000 chronic patients in the US • The estimated lifetime cost of living with spinal cord injury for a 25-year-old is $1.7 million to $5.1 million1 • A therapeutic that results in any improvement in motor, bladder
Slide 15: NVG-291 – Dramatically Repairs Spinal Cord Injury
NVG-291 – Dramatically Repairs Spinal Cord Injury S E V E R E S P I N A L C O R D I N J U RY M O D E L Representative of Placebo Group Representative of NVG-291 Group Hind legs are immobile Significant motor recovery: consistent coordination, toe clearance, tail held high consistently 15 Rink, S. et
Slide 16: Spinal Cord Injury – NVG-291 Promotes Functional Recovery
Spinal Cord Injury – NVG-291 Promotes Functional Recovery BBB Scale = Standard measure of mobility 21 = Normal function 20 # NVG-291 500ug UNPRECEDENTED ≥14 = fine motor # (N=5) RESULTS movements # 15 # Extremely high Occasional response rate coordination 10 50% Placebo Almost complete (N=20) ≤8 = l
Slide 17: NVG-291 Improves Bladder Function
NVG-291 Improves Bladder Function BLADDER DOSE RESPONSE 1.5 Void Frequency ** 100% of animals in the * two highest dose groups 1.0 had improved bladder Responders (2x SD of vehicle mean) control function NVG-291 treatment resulted 0.5 in a dose dependent improvement in bladder function 0.0 Vehicle 3
Slide 18: Multiple Sclerosis Repair: No FDA Approved Drug
Multiple Sclerosis Repair No FDA Approved Drug • ~900,000 patients in the US1 • >$30 billion market potential in the US • MS is an autoimmune disease where the immune system attacks myelin in the central nervous system • Approved drugs treat day to day symptoms and may slow disease progression, but
Slide 19: NVG-291 Remyelinates in Multiple Sclerosis
NVG-291 Remyelinates in Multiple Sclerosis POSITIVE PLACEBO NVG-291 PRECLINICAL RESULTS1 Animals treated with NVG-291 had substantially greater remyelination 3 days compared to placebo treated animals after 21 days post-lesion Histological evidence showed that the desired types of cells were migrati
Slide 20: NVG-291 Restores Motor Function in Multiple Sclerosis
NVG-291 Restores Motor Function in Multiple Sclerosis Representative of Placebo Group Representative of NVG-291 Group Score never improves from 3.5 Score improves to 0.5 in 20 days NVG-291 restored motor function in MS model1, even when administered after symptoms were fully developed 20 1Luo, F. et
Slide 21: Alzheimer's Disease Lacks Therapies to Restore Function
Alzheimer’s Disease Lacks Therapies to Restore Function • 6,000,000 patients living with Alzheimer’s in the US1 • ~910,000 new patients every year • >$300 billion market potential in the US • Treatments for Alzheimer's are limited and unsatisfactory • Symptomatic treatments are available to tempora
Slide 22: NVG-291 Pathway to Treat Alzheimer's Disease
NVG-291 Pathway to Treat Alzheimer’s Disease CSPG ACCUMULATION IN AD PATIENT BRAINS1 Preclinical studies have demonstrated (CSPGs) Brevican/GAPDH that breaking down CSPGs 2.5 improves Alzheimer's symptoms2,3 * 2.0 1.5 Removing PTPσ improves cognitive function in Alzheimer’s models4 1.0 0.5 NVG-291’s
Slide 23: NVG-291 - Phase 1 Clinical Trial In Progress
NVG-291 - Phase 1 Clinical Trial In Progress Single Ascending Dose (SAD) Cohorts – COMPLETED Conducted in healthy volunteers, the study is: • NVG-291 was well tolerated at a high dose • 170% higher than the equivalent highest dose in preclinical efficacy studies • >100x higher than the lowest effica
Slide 24: NVG-291 Efficacy Studies in Patients
NVG-291 Efficacy Studies in Patients 2022 2023 2024 • Single center, placebo controlled Spinal Cord Injury Phase 2a • Efficacy analysis includes electrophysiology, ~16 patients per arm, clinical assessments of upper and lower minimum 32 patents extremity function • Multicenter, placebo controlled Al
Slide 25: Phase 1 Clinical Trial – Current Status
Phase 1 Clinical Trial – Current Status April 2022 2022 2023 Multiple Ascending Dose Bridging Cohorts (Postmenopausal females) (Males, premenopausal females) 14-day dosing FDA 14-day dosing Submission Three dose levels 25
Slide 26: World Class Clinical Advisory Boards
World Class Clinical Advisory Boards Spinal Cord Injury Multiple Sclerosis Alzheimer’s Disease Ex-Pres., Americas Committee for Jeffrey Cummings, MD, James Guest World renowned surgeon/scientist; Originator, Neuropsychiatric Inventory Jack Antel, MD Treatment and Research in MS; ScD MD, PhD, FACS gl
Slide 27: Share and Capital Structure
Share and Capital Structure Exchange/Market: Ticker TSX: NGEN.V OTCQX: NGENF Recent Share Price CA $2.25 US $1.76 (Apr. 18, 2022) Shares Outstanding 46.3 million 63.6 million Fully Diluted (~7.1 million options, ~10.2 million warrants) Insider Ownership 10% ~Cash & Cash Equivalents CA $16.9 million
Slide 28: Upcoming Value Drivers
Upcoming Value Drivers PHASE INITIATION READOUT ADVANCED Alzheimer’s Disease 1b/2a Q4 2022 2024 CLINICAL TRIAL PROGRAM Spinal Cord Injury 2a Q4 2022 2023 Multiple Sclerosis 2 Q1 2023 2024 • Phase 1 study topline MAD data (2022) • Preclinical study results in stroke, chronic spinal cord injury and Al
Slide 29: Investment Highlights
Investment Highlights NVG-291 has the potential to redefine treatment paradigms for neurological disorders Improvement demonstrated across 6 different animal models in fine and gross motor control, sensory function, autonomic functions, visual acuity, memory & learning, in many cases unprecedented P